Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

Joan D. Beckman, Marian A. Rollins-Raval, Jay S. Raval, Yara A. Park, Marshall Mazepa, Alice Ma

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

Original languageEnglish (US)
Pages (from-to)E270-E272
JournalAmerican journal of therapeutics
Volume25
Issue number2
DOIs
StatePublished - Mar 1 2018

Bibliographical note

Funding Information:
1Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC; and 2Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC. Supported by National Institutes of Health, National Heart, Lung, and Blood Institute, Grant T32HL007149 (J.D.B.). The authors have no conflicts of interest to declare. *Address for correspondence: Division of Hematology/Oncology, Department of Medicine, University of North Carolina, 170 Manning Drive, CB 7305, Chapel Hill, NC 27599-7305. E-mail: alice_ma@med.unc.edu

Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

  • Bortezomib
  • Immune-mediated thrombocytopenia purpura

Fingerprint

Dive into the research topics of 'Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura'. Together they form a unique fingerprint.

Cite this